Terms: = Endocrine gland cancer AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184
353 results:
1. The nanobody targeting PD-L1 and cxcr4 counteracts pancreatic stellate cell-mediated tumour progression by disrupting tumour microenvironment.
Li Y; Zheng Y; Xu S; Hu H; Peng L; Zhu J; Wu M
Int Immunopharmacol; 2024 May; 132():111944. PubMed ID: 38581990
[TBL] [Abstract] [Full Text] [Related]
2. Expression and clinical value of cxcr4 in high grade gastroenteropancreatic neuroendocrine neoplasms.
Pang C; Li Y; Shi M; Fan Z; Gao X; Meng Y; Liu S; Gao C; Su P; Wang X; Zhan H
Front Endocrinol (Lausanne); 2024; 15():1281622. PubMed ID: 38524630
[TBL] [Abstract] [Full Text] [Related]
3. CRISPR du-HITI an attractive approach to targeting Long Noncoding RNA HCP5 as inhibitory factor for proliferation of ovarian cancer cell.
Moradi Z; Kazemi M; Jamshidi-Khalifelou R; Bahramnia V; Esfandmaz F; Rahnavard R; Moradgholi B; Piri-Gharaghie T
Funct Integr Genomics; 2024 Mar; 24(2):61. PubMed ID: 38507114
[TBL] [Abstract] [Full Text] [Related]
4. Exploring Theranostic Avenues in Adrenocortical Carcinoma Using Chemokine Receptor and Prostate-Specific Membrane Antigen-Directed PET/CT.
Hahner S; Higuchi T; Serfling SE; Samnick S; Fuss CT; Heinze B; Buck AK; Schirbel A; Fassnacht M; Werner RA
Clin Nucl Med; 2024 Apr; 49(4):369-370. PubMed ID: 38350087
[TBL] [Abstract] [Full Text] [Related]
5. Unraveling the impact of cancer-associated fibroblasts on hypovascular pancreatic neuroendocrine tumors.
Lai TY; Chiang TC; Lee CY; Kuo TC; Wu CH; Chen YI; Hu CM; Maskey M; Tang SC; Jeng YM; Tien YW; Lee EYP; Lee WH
Br J Cancer; 2024 Apr; 130(7):1096-1108. PubMed ID: 38341509
[TBL] [Abstract] [Full Text] [Related]
6. Exhausted Tumor-infiltrating CD39+CD103+ CD8+ T Cells Unveil Potential for Increased Survival in Human Pancreatic cancer.
Gorchs L; Fernández-Moro C; Asplund E; Oosthoek M; Solders M; Ghorbani P; Sparrelid E; Rangelova E; Löhr MJ; Kaipe H
Cancer Res Commun; 2024 Feb; 4(2):460-474. PubMed ID: 38335302
[TBL] [Abstract] [Full Text] [Related]
7. Single-cell analysis reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of ovarian cancer.
Zhang L; Cascio S; Mellors JW; Buckanovich RJ; Osmanbeyoglu HU
Commun Biol; 2024 Jan; 7(1):20. PubMed ID: 38182756
[TBL] [Abstract] [Full Text] [Related]
8. Single-cell RNA-seq reveals MIF-(CD74 + cxcr4) dependent inhibition of macrophages in metastatic papillary thyroid carcinoma.
Chen W; Yu X; Li H; Yuan S; Fu Y; Hu H; Liu F; Zhang Y; Zhong S
Oral Oncol; 2024 Jan; 148():106654. PubMed ID: 38061122
[TBL] [Abstract] [Full Text] [Related]
9. EPI-X4, a cxcr4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models.
Sagini MN; Zepp M; Eyol E; Ali DM; Gromova S; Dahlmann M; Behrens D; Groeschel C; Tischmeier L; Hoffmann J; Berger MR; Forssmann WG
Peptides; 2024 May; 175():171111. PubMed ID: 38036098
[TBL] [Abstract] [Full Text] [Related]
10. The importance of cxcr4 expression in tumor stroma as a potential biomarker in pancreatic cancer.
Bodoque-Villar R; Padilla-Valverde D; González-López LM; Muñoz-Rodríguez JR; Arias-Pardilla J; Villar-Rodríguez C; Gómez-Romero FJ; Verdugo-Moreno G; Redondo-Calvo FJ; Serrano-Oviedo L
World J Surg Oncol; 2023 Sep; 21(1):287. PubMed ID: 37697316
[TBL] [Abstract] [Full Text] [Related]
11. MUC16 stimulates neutrophils to an inflammatory and immunosuppressive phenotype in ovarian cancer.
Wu Y; Liu Q; Xie Y; Zhu J; Zhang S; Ge Y; Guo J; Luo N; Huang W; Xu R; Liu S; Cheng Z
J Ovarian Res; 2023 Aug; 16(1):181. PubMed ID: 37644468
[TBL] [Abstract] [Full Text] [Related]
12. Tissue Expression and Prognostic Role of CXCL12 and cxcr4 in High-grade Serous Ovarian Carcinoma.
Lim H; Kim SI; Kim EN; Lee M; Lee C; Kim JW; Chung HH
Anticancer Res; 2023 Jul; 43(7):3331-3340. PubMed ID: 37351997
[TBL] [Abstract] [Full Text] [Related]
13. Increased SPRY1 expression activates NF-κB signaling and promotes pancreatic cancer progression by recruiting neutrophils and macrophages through CXCL12-cxcr4 axis.
Shi T; Li X; Zheng J; Duan Z; Ooi YY; Gao Y; Wang Q; Yang J; Wang L; Yao L
Cell Oncol (Dordr); 2023 Aug; 46(4):969-985. PubMed ID: 37014552
[TBL] [Abstract] [Full Text] [Related]
14. Glutamine deprivation induces ferroptosis in pancreatic cancer cells.
Xiao Z; Deng S; Liu H; Wang R; Liu Y; Dai Z; Gu W; Ni Q; Yu X; Liu C; Luo G
Acta Biochim Biophys Sin (Shanghai); 2023 Mar; 55(8):1288-1300. PubMed ID: 36942991
[TBL] [Abstract] [Full Text] [Related]
15. Comprehensive pan-cancer analysis of role of GPRASP1, associated with clinical outcomes, immune microenvironment, and immunotherapeutic efficiency in pancreatic cancer.
Du J; Chen Y; Liu G; Zeng Q; Zhou N; Du D
Pathol Res Pract; 2023 Mar; 243():154374. PubMed ID: 36801507
[TBL] [Abstract] [Full Text] [Related]
16. cancer-associated fibroblasts contribute to cancer metastasis and apoptosis resistance in human ovarian cancer via paracrine SDF-1α.
Dai JM; Sun K; Li C; Cheng M; Guan JH; Yang LN; Zhang LW
Clin Transl Oncol; 2023 Jun; 25(6):1606-1616. PubMed ID: 36593384
[TBL] [Abstract] [Full Text] [Related]
17. Effect of tocopherol conjugation on polycation-mediated siRNA delivery to orthotopic pancreatic tumors.
Tang S; Kapoor E; Ding L; Yu A; Tang W; Hang Y; Smith LM; Sil D; Oupický D
Biomater Adv; 2023 Feb; 145():213236. PubMed ID: 36512927
[TBL] [Abstract] [Full Text] [Related]
18. Exosomal miR-655-3p inhibits growth, and invasion and macrophage M2 polarization through targeting cxcr4 in papillary thyroid carcinoma.
Qiao L; Dong C; Jia W; Ma B
Acta Biochim Pol; 2022 Dec; 69(4):773-779. PubMed ID: 36512648
[TBL] [Abstract] [Full Text] [Related]
19. The prognostic significance of cxcr4 and SDF-1 in differentiated thyroid cancer depends on CD8+ density.
Wilhelm A; Lemmenmeier I; Lalos A; Posabella A; Kancherla V; Piscuoglio S; Delko T; von Flüe M; Glatz K; Droeser RA
BMC Endocr Disord; 2022 Nov; 22(1):292. PubMed ID: 36419107
[TBL] [Abstract] [Full Text] [Related]
20. cxcr4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic cancer: CXCL12 Predicts Survival of Radically Resected Patients.
D'Alterio C; Giardino A; Scognamiglio G; Butturini G; Portella L; Guardascione G; Frigerio I; Montella M; Gobbo S; Martignoni G; Napolitano V; De Vita F; Tatangelo F; Franco R; Scala S
Cells; 2022 Oct; 11(21):. PubMed ID: 36359736
[TBL] [Abstract] [Full Text] [Related]
[Next]
